Clinical trial · Interventional
Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis
NCT05045248CI-TRIAL-00053912completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is aimed at assessing the efficacy of Apraclonidine eye drops in the treatment of ptosis secondary to myasthenia gravis.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myasthenia Gravis | — | UNRESOLVED | — |
| Ocular Myasthenia Gravis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Apraclonidine Hcl 0.5% Oph Soln | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patients
- description
- Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye. Objective measurements of ptosis will be taken before drug administration and at 1, 5, 30, 60 minutes after drug administration in order to analyze any change in ptosis.
- interventionNames
- Drug: Apraclonidine Hcl 0.5% Oph Soln
Primary outcomes (4)
- measure
- Change in palpebral fissure height (PF)
- timeFrame
- Before administration, at 1, 5, 30, and 60 minutes after administration
- description
- Change in PF measurements
- measure
- Change in marginal reflex distance-1 (MRD1)
- timeFrame
- Before administration, at 1, 5, 30, and 60 minutes after administration
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged 18 or older with a diagnosis of ocular or generalized myasthenia gravis with ocular involvement. Exclusion Criteria: * Patients receiving mono-amino-oxidase inhibitors. * Patients with history of hypertension, cardiac, or cerebrovascular disease. * Women with confirmed pregnancy.
References
Publications (1)
- DERIVEDAgha M, Ismail H, Sawaya R, Salameh J. Efficacy of apraclonidine eye drops in treating ptosis secondary to myasthenia gravis: A pilot clinical trial. Muscle Nerve. 2023 Aug;68(2):206-210. doi: 10.1002/mus.27851. Epub 2023 May 31. PMID 37259693